Brainstorm Cell Therapeutics Inc. (GHDN.F)

0,3635 -0,0320 (-8,09%) Börsenschluss: 08:05AM CEST

Brainstorm Cell Therapeutics Inc.

1325 Avenue of Americas
28th Floor
New York, NY 10019
United States
201 488 0460
https://www.brainstorm-cell.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 29

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Chaim Lebovits	President & Co-CEO	815,8k	N/A	1971
Dr. Stacy R. Lindborg Ph.D.	Co-Chief Executive Officer	697,25k	N/A	1971
Dr. Irit Arbel DSc, Ph.D.	Co-Founder & Independent Vice Chair of the Board	N/A	N/A	1960
Ms. Alla Patlis CPA, M.B.A.	Interim CFO & Controller	121,54k	N/A	1987
Mr. Uri Yablonka	Executive VP, Chief Business Officer, Secretary & Director	229,35k	N/A	1977
Dr. Daniel Offen Ph.D.	Chief Scientific Advisor	N/A	N/A	N/A
Ms. Mary Kay Turner	Senior Vice President of Patient Advocacy & Government Affairs	N/A	N/A	N/A
Dr. Ibrahim Dagher M.D.	Executive VP & Chief Medical Officer	N/A	N/A	1969

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.

Corporate Governance

Brainstorm Cell Therapeutics Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 5. Die grundlegenden Scores sind Audit: 9, Vorstand: 3, Shareholderrechte: 2, Kompensation: 7.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.